Viloxazine in the treatment of endogenous depression. A standard (amitriptyline) controlled clinical study

In a double-blind clinical trial with 20 patients suffering from endogenous depression statistically significant changes (improvement) were present in the scores of all assessment instruments. Although no statistically significant differences occurred between the groups, significant improvement on the HAM-D occurred earlier for amitriptyline and significant improvement occurred earlier on HAM-A for viloxazine. 2 patients were discontinued due to adverse reactions; one for nausea and vomiting while recieving viloxazine and one for paroxysmal atrial tachycardia while receiving amitriptyline. Other than for 1 patient who developed syncope and orthostatic hypotension and the patient who developed paroxysmal atrial tachycardia, there were no clinically significant changes in pulse rate, blood pressure and weight.

Duke Scholars

Author William Herman Wilson Psychiatry & Behavioral Sciences, Behavioral Medicine & Neur ...